UNSPSC 51373444: Codeine/guaifenesin/pseudoephedrine/triprolidine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373444 Codeine/guaifenesin/pseudoephedrine/triprolidine is a Commodity code that in recent state and local procurement activity encompasses a broader range of pharmaceutical products than its nominal title suggests. Recent solicitations show state and local health agencies and cooperative purchasing alliances buying generic multi-source pharmaceuticals and over-the-counter (OTC) products through both direct procurement and cooperative contracting vehicles. The issuing bodies include county health departments and state-administered cooperative purchasing alliances that aggregate demand across multiple jurisdictions; Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement (administering the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) appear in the recent record.

Geographic activity spans Florida and Minnesota, with MMCAP's purchasing extending to participating state and local facilities in Oregon as well. Recent representative opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building (response due July 26, 2023); and MMCAP's S1070000015802, a Request for Proposal posted January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with responses due March 26, 2026 and awarded vendors effective July 1, 2026. Cooperative purchasing vehicles appear to be a primary channel, with MMCAP's RFP emphasizing compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and pricing flexibility through multiple pricing structures; both solicitations require comprehensive insurance and federal/state regulatory compliance.